Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04776941 · ClinicalTrials.gov registry record · NA

Expressive Writing for the Management of Stress in Cancer Survivors

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
414
Enrollment target
1
Study location

NCT04776941: Recruiting NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT04776941 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 414 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04776941, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
414 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times.

Interventions

  • OTHER Quality-of-Life Assessment
  • BEHAVIORAL Behavioral Intervention

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 414 participants
Start Date 2020-08-07
Est. Completion 2028-12-31
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What NCT04776941 shows while recruiting

NCT04776941 is an interventional study that assigns participants to a tested intervention. The registered 414 participants enrollment target is mid-sized for trials with a published cap, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (64% lower).

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04776941 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04776941 about?

NCT04776941 is a clinical study titled "Expressive Writing for the Management of Stress in Cancer Survivors". This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and d...

What is the current status of trial NCT04776941?

This trial is currently recruiting. It is a NA study. The enrollment target is 414 participants. The study started on 2020-08-07. Estimated completion is 2028-12-31.

What conditions does trial NCT04776941 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT04776941?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Behavioral Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT04776941?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04776941 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04776941's enrollment target sits among peer trials

414 35th of 176 higher than 142 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06792552 · 414 participants · Phase 1

    A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

  • NCT05142605 · 415 participants · NA

    Evaluation of Grief Therapy Approaches for Bereaved Parents

  • NCT03592472 · 413 participants · Phase 3

    A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

  • NCT06697197 · 413 participants · Phase 1

    A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04776941, the US trial registry maintained by the National Library of Medicine. NCT04776941 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.